Therapeutics Discovery, Phase 1 and early phase clinical trial activities are the target of Kingdom of Saudi Arabia to enter the world of making and marketing new medicines.
In the last decade 56% of novel therapies are originated from the Academia and Biotech companies and 71% were “me-too” drugs coming from the Pharmaceutical companies.
The challenge for introducing new therapies into the market or development pipeline is based on the better understanding of the diseases biology and it is becoming apparent that the “single target for single disease” may be an outdated concept. A new approach being pursued is to dissect the molecular basis of the diseases and in this regard, a future trend includes using the immune system and cell therapy to fight the diseases to discover and develop new therapies for inflammatory and proliferative diseases. Also there is a focus to develop better drug delivering system based on Nanotechnology.
Based on this concept, KAIMRC as a prime biomedical research institute in the KSA and the region, is leading the path to establish therapeutics discoveries and development platforms. Moreover, with renowned researchers, medical doctors, experts and professional clinical trial facilities, KAIMRC is playing important roles in clinical trials aiming to enter phase 1 and early phase new drug development.
KAIMRC conference on “Therapies Discoveries From Bench to First In Humans Trials” will provide an interdisciplinary forum for scientific investigators interested in the latest trend in therapeutics discoveries approaches, advanced drug delivery system and clinical trials that would be covered in the following sessions:
1- Phase I Clinical Trials: Challenges and Opportunities.
2- Disease Specific Early Clinical Trials.
3- Therapeutics Discovery: Niches and Paradigm.
4- Advanced and Targeted Drug Delivery Technologies.
5- Small molecule drugs vs Biologicals (Antibody and CART).
Nanotechnology, Molecular Pharmacology, General, Cell Biology, Cancer Therapy, Cancer, Biotechnology
King Abdullah International Medical Research Center’s (KAIMRC)